[go: up one dir, main page]

MX2010001754A - Derivados de azepina como inhibidores de gamma secretasa. - Google Patents

Derivados de azepina como inhibidores de gamma secretasa.

Info

Publication number
MX2010001754A
MX2010001754A MX2010001754A MX2010001754A MX2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A
Authority
MX
Mexico
Prior art keywords
gamma
secretase inhibitors
azepine derivatives
azepine
derivatives
Prior art date
Application number
MX2010001754A
Other languages
English (en)
Inventor
Melina Joy Hope Miller
Warren Jaye Porter
Jon Kevin Reel
Almudena Rubio-Esteban
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2010001754A publication Critical patent/MX2010001754A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen compuestos de fórmula (I), composiciones farmacéuticas que los comprenden, y métodos para su uso.
MX2010001754A 2007-08-14 2008-08-04 Derivados de azepina como inhibidores de gamma secretasa. MX2010001754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95572007P 2007-08-14 2007-08-14
PCT/US2008/072049 WO2009023453A1 (en) 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors

Publications (1)

Publication Number Publication Date
MX2010001754A true MX2010001754A (es) 2010-05-14

Family

ID=39811736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001754A MX2010001754A (es) 2007-08-14 2008-08-04 Derivados de azepina como inhibidores de gamma secretasa.

Country Status (11)

Country Link
US (1) US8188069B2 (es)
EP (1) EP2178844A1 (es)
JP (1) JP5385904B2 (es)
KR (1) KR101136260B1 (es)
CN (1) CN101778826B (es)
AU (1) AU2008287124B2 (es)
BR (1) BRPI0815135A2 (es)
CA (1) CA2694209C (es)
EA (1) EA017286B1 (es)
MX (1) MX2010001754A (es)
WO (1) WO2009023453A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
US10143711B2 (en) 2008-11-24 2018-12-04 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
US20130060023A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
WO2014039908A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells
US9249157B2 (en) 2012-09-21 2016-02-02 Bristol-Myers Squibb Company Tricyclic heterocycle compounds
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
WO2014047370A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
JP2015531792A (ja) 2012-09-21 2015-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ １，４−ベンゾジアゼピノン化合物のプロドラッグ
WO2014047374A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
WO2014047397A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors
JP2015533811A (ja) 2012-09-21 2015-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎ−置換ビス（フルオロアルキル）１，４−ベンゾジアゼピノン化合物
US9492469B2 (en) 2013-04-04 2016-11-15 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
WO2015073524A1 (en) * 2013-11-12 2015-05-21 Drexel University Novel methods of treating or preventing alzheimer's disease
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
US11466252B2 (en) 2016-01-29 2022-10-11 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
ES2881801T3 (es) 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
WO2017180385A1 (en) 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
CN109689071B (zh) 2016-05-16 2023-05-30 通用医疗公司 肺上皮工程中的人气道干细胞
CA3025024A1 (en) 2016-05-20 2017-11-23 Eli Lilly And Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
EP3554502A4 (en) 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
AU2020307471A1 (en) 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3812952B2 (ja) * 1996-12-23 2006-08-23 エラン ファーマシューティカルズ，インコーポレイテッド シクロアルキル、ラクタム、ラクトンおよびその関連化合物およびその医薬組成物、並びに該化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
WO2004080983A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel lactams and uses thereof

Also Published As

Publication number Publication date
KR20100032924A (ko) 2010-03-26
CA2694209C (en) 2013-09-17
JP5385904B2 (ja) 2014-01-08
EA017286B1 (ru) 2012-11-30
US20100197660A1 (en) 2010-08-05
CN101778826B (zh) 2012-10-31
EP2178844A1 (en) 2010-04-28
CN101778826A (zh) 2010-07-14
WO2009023453A1 (en) 2009-02-19
JP2010536766A (ja) 2010-12-02
AU2008287124B2 (en) 2013-06-06
CA2694209A1 (en) 2009-02-19
KR101136260B1 (ko) 2012-04-19
US8188069B2 (en) 2012-05-29
EA201070278A1 (ru) 2010-06-30
AU2008287124A1 (en) 2009-02-19
BRPI0815135A2 (pt) 2015-02-03

Similar Documents

Publication Publication Date Title
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
MX2009000884A (es) Derivados de piridizinona.
MY153915A (en) Organic compounds
MX2011005934A (es) Compuestos organicos.
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
AU2010246749A8 (en) Thiophene derivatives
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
MY151986A (en) Adamantyl diamide derivatives and uses of same
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX2012004780A (es) Inhibidores de akt.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
TW200745084A (en) Novel compounds
TW200738653A (en) Anthranilamide/2-amino-heteroarene carboxamide derivatives
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
UA99787C2 (en) Lactams as beta secretase inhibitors
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
TW200738627A (en) Trialkylsilyl-indoles
SG158091A1 (en) Imidazoazepinone compounds
MX2010004604A (es) Derivados de pirazol como inhibidores de 5-lo.
PT1877367E (pt) Derivados do acetileno
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
MX2009013667A (es) Inhibidores triciclicos de hidroxiesteroide deshidrogenasas.

Legal Events

Date Code Title Description
FG Grant or registration